Innate Immuno
- Short interest
- 0.19%
- +0.11 pp 30d
- as of 27 June 2018
- Reported shorts
- 79K
- Shares on issue
- 41.023M
Innate Immuno (IIL) Short Interest
Innate Immuno (ASX:IIL) had 0.19% of shares reported as short positions as of 27 June 2018, representing 78,954 shares. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Innate Immuno
Innate Immuno is a biotechnology company focused on developing innovative immunotherapy treatments. The company aims to address unmet medical needs by leveraging its proprietary technology to enhance the body's immune response.
Company profile →Innate Immuno (ASX:IIL) has 0.19% of its shares on issue reported as short positions as of 27 June 2018, or about 78,954 shares. Over the past 30 days that figure has risen 0.11 percentage points, and over 90 days it has risen 0.18 percentage points. Its highest recorded short interest was 0.48% in March 2018. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Be the first to discuss IIL
Start a research thread or post the first pulse update